ARID1A Stimulates Notch-TLL1 Signaling to Induce Cancer-Associated Fibroblast Activation and Intrahepatic Cholangiocarcinoma Development.

ARID1A upregulation in intrahepatic cholangiocarcinoma sustains Notch signaling and promotes tumor progression through TLL1 activation.

• Why it matters: Understanding the molecular mechanisms driving ICC is crucial for developing targeted therapies, especially since ICC has a prominent desmoplastic stroma and limited treatment options.
• What they did: The study examined ARID1A's role in ICC, showing it stabilizes NICD1 to maintain Notch signaling, with TLL1 acting downstream to activate hepatic stellate cells and promote fibrosis and tumor growth; they also identified acarbose as a TLL1 inhibitor through virtual screening.
• The result: Inhibiting TLL1 with acarbose reduced HSC activation, collagen deposition, and tumor development, suggesting the ARID1A/Notch/TLL1 axis as a potential therapeutic target for ARID1A-high ICC patients.